We showed increasing HIV prevalence among TB patients in Kazakhstan. HIV was not an independent risk factor for MDR-TB, but risk factors were largely overlapping and we did identify subgroups at particular risk of HIV-MDR-TB co-infection, notably drug users. Enhanced efforts are necessary to provide care to these socially vulnerable populations.
ALTHOUGH OUTBREAKS of multidrug-resistant (MDR-) and extensively drug-resistant tuberculosis (XDR-TB) among human immunodefi ciency virus (HIV) patients have been widely reported in nosocomial and other congregate settings, there is less clarity on the association between drug resistance and HIV among TB patients in communities, 1 mainly due to lack of information. Only 17 countries and one territory were able to report drug-resistant TB (DR-TB) notifi cation data disaggregated by HIV status to the World Health Organization. 2 The combined data did not support a clear association between HIV status and presence of MDR-TB (pooled odds ratio [OR] 1.4, 95% confi dence interval [CI] 0.7-3.0). Of interest, a positive association was present in Eastern European countries, as also noted previously. 3 A review also showed confl icting results. 4 Both drug resistance and HIV worsen the TB disease burden among individuals and are a threat to global TB control. Understanding the relationship between HIV infection and drug-resistant TB at the population level is critical to identifying high-risk groups in need of additional support. 2 In co-infected patients, a high proportion of patients die before or shortly after the start of anti-tuberculosis treatment. 5, 6 Isoniazid preventive therapy (IPT) and antiretroviral therapy (ART) reduce the risk of developing active TB in HIV-infected persons with latent TB infection, and ART improves TB treatment outcomes. 7 Different reasons for the association of DR-TB and HIV have been proposed. 8 Newly developed drugresistant strains appear earlier among HIV-infected TB patients as they progress more rapidly to disease after infection. Malabsorption of drugs, drug interactions and intermittent rifamycin use may lead to suboptimal plasma concentrations and acquisition of (further) drug resistance, facilitating further transmission. HIV and DR-TB may also occur in the same population of TB patients due to joint risk factors.
We examined the relationship between DR-TB and HIV based on routine data from Kazakhstan, where all TB cases are eligible for HIV testing, culture and
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Converging risk factors for HIV and MDR-TB 527 drug susceptibility testing (DST). Kazakhstan is a country with a low HIV prevalence but with a high prevalence of drug resistance among TB patients. HIV prevalence among the population aged 15-49 years was estimated to be 0.1 in 2009. 9, 10 The 2002 drug resistance survey showed that MDR-TB was present in 14% of new TB patients and 56% of previously treated patients. 11, 12 
METHODS

Organization of tuberculosis and HIV/AIDS services
Civil TB services in Kazakhstan are coordinated by the National Centre for Tuberculosis Problems (NCTP) and oblast/city TB centres, with a TB dispensary in every rayon. In each of the 14 oblasts and two cities (Almaty and Astana), at least one laboratory performs smear microscopy, culture and DST for civil TB patients. From 2007, diagnostic specimens from TB patients were to be cultured and tested for drug susceptibility. Smears are examined using regular light microscopy, and sputum is usually cultured on Löwenstein-Jensen medium. Solid culture isolates are examined for DST using the absolute concentration method. Initial DST includes testing for the fi rst-line drugs isoniazid (INH), rifampicin (RMP), ethambutol and streptomycin. Patients with resistance to both INH and RMP (i.e., MDR-TB) are eligible for DST against second-line drugs. The National Reference Laboratory (NRL) for TB is located at the NCTP. External quality assurance is organised by the Supranational Reference Laboratory in Borstel, Germany.
The current TB surveillance system includes civil TB cases from 2007 onwards. In 2009, a data quality system was established, which has improved data completeness and data quality, also retrospectively from 2007 onwards. 13 Since 2002, all TB patients have been offered HIV testing. Samples are sent to and tested at the HIV/AIDS centres, whose services are organised by the Republican HIV/AIDS centre and 16 HIV/AIDS centres in the 14 oblasts and two cities. HIV-positive individuals should be regularly checked for TB at the primary health care units. TB suspects are referred to TB dispensaries for diagnostic testing.
Data collection and analysis
Routine data from the electronic national TB register were extracted for 2007-2011 in April 2012. Information on population size to calculate notifi cation rates were obtained from the Republican Agency of Statistics. 14 Alcoholism and drug use are captured based on diagnosis by the physician; no standardised defi nitions of alcoholism and drug use were used. Information on treatment history was not available from the electronic register for patients who transferred in during treatment. Drug resistance profi les were grouped as susceptible to all fi rst-line drugs tested for, monoresistance to one of these drugs, polyresistance (resistance to several of these drugs but not to both INH and RMP) and multidrug resistance (resistance to both INH and RMP). Univariate logistic regression was performed to calculate ORs and assess characteristics associated with HIV and MDR-TB. Variables with P < 0.25 were considered for inclusion in multivariable models. By backward elimination, the most parsimonious model was selected, using -2 log likelihood ratio testing. As HIV infection was our main determinant for the association with MDR-TB, this parameter was retained in the multivariate model assessing factors associated with MDR-TB. As all TB patients in Kazakhstan are eligible for HIV testing and culture/DST, testing is not selective and analyses were not adjusted for geographic clustering. All data were analysed using SPSS for Windows, version 18 (IBM Corporation, Somers, NY, USA).
As the project used routine notifi cation data, no ethical clearance was needed.
RESULTS
Patient characteristics
In 2007-2011, a total of 146 416 patients diagnosed with TB were notifi ed and started on treatment. The number of TB patients diagnosed decreased yearly; the corresponding notifi cation rate per 100 000 population went down from 184 in 2007 to 156 in 2011, an average relative annual decrease of 4%. HIV testing results were available for 142 349 (97.2%). Table  1 shows the distribution of all notifi ed TB cases with an HIV test result available by year, patient category and socio-demographic variables. Half of all TB patients diagnosed were young adults aged 15-34 years, and 60.5% were male. Excluding transfer-in patients for whom treatment history was unavailable in the electronic register, 20% of patients were diagnosed with new smear-positive TB, 45% with new smearnegative TB and 35% with previously treated TB. Table 1 shows the proportion of TB patients with a positive HIV test result, which increased from 0.6% in 2007 to 1.5% in 2011, an average relative annual increase of 15%.
HIV testing results
Within patient groups, HIV prevalence was highest among drug-using TB patients (52.8%). In the adjusted analysis, other factors associated with higher HIV prevalence were male sex, age 25-44 years, urban residency, homelessness, alcoholism and a history of imprisonment ( Table 1 ). The positive association with HIV among patients returning after default or failure disappeared in multivariate analysis. However, among new patients, smear-positive TB remained associated with a higher HIV prevalence (Table 2) .
Smear, culture and drug susceptibility testing results
Smear results were available for 98.0% of all TB patients with an HIV test result available. Among new patients, 31.2% were smear-positive. Of all smearpositive TB patients, 69.2% had a positive culture result registered compared to 16.6% of all smearnegative TB patients. Overall, 41.6% of patients had a positive smear at diagnosis, 38.6% a positive culture, and 51.7% either a positive smear or culture. DST results were available for 35.7%, corresponding to 92.7% of culture-positive cases.
Among the 50 859 notifi ed TB patients with an HIV test result and known DST profi le, 38.3% were susceptible to all fi rst-line TB drugs, 8.5% were monoresistant to one of these fi rst-line drugs, 17.1% were polyresistant and 36.1% had MDR-TB. The prevalence of MDR-TB showed no clear trend over the period from 2007 to 2011, even when stratifi ed by new and retreatment patients (data not shown).
MDR-TB was most prevalent among patients who had failed previous anti-tuberculosis treatment (56%), and among those who relapsed after successful treatment (48%), and was lowest among new patients (27%) ( Table 3) . In univariate analysis, MDR-TB prevalence was inversely associated with age, and was 
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529 not associated with sex or age (data not shown). The prevalence of MDR-TB was higher among urban TB patients, and homeless, drug-using and previously imprisoned patients. In adjusted analysis, statistically signifi cant risk factors for MDR-TB were age, patient category, urban residency, homelessness and a history of imprisonment (Table 3) .
Association between HIV status and drug resistance
Overall, for patients with DST and HIV test results, 65.0% were HIV-negative and did not have MDR-TB, 0.9% were HIV-positive only, 33.5% had MDR-TB only and 0.6% were positive for both HIV and MDR-TB. In univariate analysis, HIV infection status was associated with an increased prevalence of MDR-TB Table 3 ).
DISCUSSION
The results show a high prevalence of MDR-TB and increasing HIV prevalence among TB patients in Kazakhstan in the period 2007-2011. In this 5-year national cohort of TB patients, HIV was not an independent risk factor for MDR-TB. However, risk factors were largely overlapping, and we did identify subgroups at particular risk for HIV-MDR-TB co-infection. The overall percentage of patients with MDR-TB was 36%, and as expected, it was higher among retreatment (39-56%) patients than new (27%) patients. Compared with results from the 2002 survey, the prevalence of MDR-TB among new TB patients has increased, 11 an indication of ongoing transmission of MDR-TB in Kazakhstan. Another indication is the increased prevalence of MDR-TB in younger patients. As the youngest patients were infected most recently, this implies that the transmission of MDR-TB may still be increasing in Kazakhstan, or that it increased until recently. A similar age-specifi c pattern was recently observed in Minsk, Belarus. 15 Coverage of MDR-TB treatment was recently expanded, from below 25% before 2008 to 75% in 2010-2011. Experiences from other countries show that it will take at least 10-15 years before good MDR-TB control translates into reduced transmission and a decrease in the prevalence of MDR-TB among new TB patients. 2, 16 HIV prevalence among TB patients in Kazakhstan is still low, but rising, from 0.6% in 2007 to 1.5% in 2011. This observation among TB patients is in accordance with the rapidly evolving HIV epidemic in Eastern Europe and Central Asia, 10 which is driven by networks of injecting drug users. HIV prevalence among TB patients was highest in the young and among male adults, and was strongly associated not only with drug use but also with homelessness, alcoholism and a history of incarceration. Prison history, drug use and homelessness, but not alcoholism, were associated with having MDR-TB. The risk factors for MDR-TB and HIV in Kazakhstan are largely overlapping, and this dual epidemic is therefore converging in certain social groups, in line with previously hypothesised reasons for an expected association. 8 Recent modelling predicted that preferential mixing of HIV-positive individuals would promote the transmission of MDR-TB, but the longer-term effect on MDR-TB prevalence within this group may be less pronounced and even greatly diminished if MDR-TB also spreads beyond these groups. 17 The already high levels of MDR-TB in 2002 among all TB patients show that this is the case in Kazakhstan. 11 Using univariate analysis, we found a 20% higher prevalence of MDR-TB among HIV-positive patients than among HIV-negative patients, in accordance with cross-sectional data from Eastern European countries. 2, 3 This association disappeared after adjustment for confounding socio-economic factors, such as drug use. Among registered TB patients with both DST and HIV testing results available, on average 0.6% of TB patients were positive both for HIV and MDR-TB, but the individual risk varied greatly. Among drug users, this percentage was 12.5%. In reality, this portion may be even higher, as access to and coverage by the (TB) health care system is expected to be weaker for this socially vulnerable group. 18 As a result of late detection, and the high early case fatality rate, a proportion of co-infected patients may already have died before MDR-TB diagnosis. Social groups with key social determinants of HIV and/or MDR-TB would benefi t from active case fi nding and support for patients to complete treatment. 19, 20 We observed a lower HIV prevalence among new sputum smear-negative TB patients than among new sputum smear-positive TB patients. HIV-positive TB patients are known to be more likely to have extrapulmonary TB, and those with pulmonary TB are less often smear-positive due to lower bacillary loads. 21 Our counterintuitive fi nding can be explained by the active case-fi nding strategy, whereby about 70% of the adult population is targeted for yearly screening by tuberculin skin testing and fl uorography. This may result in increased and early case fi nding, leading to a higher proportion of smear-negative TB among HIVnegative TB patients. This correlates with the high proportion (69%) of smear-negative diagnoses among new TB patients. In Uzbekistan, another Central Asian country where mass TB screening is also still in place, the argument that mass radiography would identify TB patients at an earlier stage, before they become smear-positive, could not be substantiated. 22 Mass screening does entail a risk of overdiagnosis of pulmonary TB, and the very low culture yield among smear-negative TB cases we observed leaves room for this possibility.
There are several limitations to our study. First, our data comprised only cases notifi ed in the civil health care system, excluding TB patients notifi ed in the penitentiary system. It is expected that the prevalence of both HIV and MDR-TB is higher among incarcerated patients, as it is for patients with a prison history. However, the annual number of penitentiary patients notifi ed was very low: 731 in 2011, 2.8% of the number of civilian cases. Second, although HIV testing coverage was almost complete, at 97.2%, DST was not, mostly due to the low yield of culture.
The low culture yield (16.6%) in new sputum smear-negative patients may be explained in part by active case fi nding. However, in addition, 30.8% of cultures from smear-positive patients were registered as negative. We do not expect that this has infl uenced the conclusions of this study, as all diagnostic samples are targeted for DST and selective resistance testing is not expected.
The distribution of characteristics most associated with the risk of both HIV and MDR-TB was very similar. The most striking differences between the patient population with and without DST results available can be explained by expected differences in bacteriological confi rmation: among all patients with an HIV test result, 58% were new cases (18% smearpositive, 40% smear-negative), while among those who also had a DST result, 48% were new cases (33% smear-positive, 15% smear-negative). Nevertheless, the reasons for the low culture yield should be investigated and actions taken to increase the yield of culture/DST. Potential reasons are long transportation times due to the vastness of the country, or overrigorous decontamination. Another possibility is that some samples are not inoculated at all, and that results are actually missing. Third, drug use and alcohol addiction in Kazakhstan is assessed by experienced TB physicians, but no defi nitions are applied. The HIV prevalence of over 50% among TB patients registered as using drugs is, however, consistent with a high proportion of injecting drug users. Fourth, treatment history was not known for the 10% of patients who transferred in. However, it seems that they are not a highly selected group, given that the HIV and MDR-TB prevalence in this group were close to the average HIV and MDR-TB prevalence among the total TB population registered.
In conclusion, our analysis revealed a great deal of overlap of risk factors for MDR-TB and HIV among TB patients in Kazakhstan. Taking into account these confounders, no association at an individual patient level was present between HIV and MDR-TB. These so cially vulnerable individuals are nevertheless at increased risk of HIV positivity and of contracting DR-TB, which increases their risk of mortality, complicates patient management and may facilitate transmission of MDR-TB. Enhanced efforts are necessary to provide care to these populations, including active case fi nding, ART for HIV-positive individuals to prevent the development of (MDR-) TB, and psychosocial support to successfully fi nish their (MDR-) TB treatment. 0; IC95% 0,86-1,2) . Globalmente, de los pacientes TB que contaban con resultados de la DST y del VIH, el 65,0% era negativo para el VIH y no presentaba TB-MDR, el 33,5% presentaba solo TB-MDR, el 0,9% era solo VIH y el 0,6% era positivo en ambos aspectos. De los pacientes consumidores de drogas, el 12,5% presentaba una prueba positiva al VIH y TB-MDR. C O N C L U S I Ó N : En el presente estudio se pone en evidencia un aumento de la prevalencia del VIH en los pacientes TB en Kazajistán. El VIH no representó un factor de riesgo independiente de padecer TB-MDR, pero se observó una amplia superposición de los factores de riesgo y se reconocieron subgrupos con un riesgo particular de sufrir coinfección por el VIH y TB-MDR, en especial los consumidores de drogas. Es preciso reforzar las iniciativas encaminadas a prestar atención a estas poblaciones socialmente vulnerables.
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